Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798317 · ClinicalTrials.gov registry record · Phase 3
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
A Phase 3 study, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT00798317 is a Phase 3 study that has completed, run by ThromboGenics. The registered enrollment target is 326 participants.
The verdict
NCT00798317, a Phase 3 study, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition, including macular hole closure, without need for vitrectomy. This clinical trial is justified because the sponsor believes the potential benefits outweigh the potential risks.
Interventions
- DRUG Placebo
- DRUG Ocriplasmin 125µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00798317
The ClinicalTrials.gov registry entry for NCT00798317 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00798317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00798317 about?
NCT00798317 is a clinical study titled "Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.". This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition,...
What is the current status of trial NCT00798317?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2008-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00798317?
The interventions under investigation include: Placebo (DRUG), Ocriplasmin 125µg (DRUG).
Who is sponsoring clinical trial NCT00798317?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.